Luigi Salvagno

1.2k total citations
46 papers, 618 citations indexed

About

Luigi Salvagno is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Luigi Salvagno has authored 46 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pathology and Forensic Medicine, 16 papers in Oncology and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Luigi Salvagno's work include Lymphoma Diagnosis and Treatment (23 papers), Lung Cancer Treatments and Mutations (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Luigi Salvagno is often cited by papers focused on Lymphoma Diagnosis and Treatment (23 papers), Lung Cancer Treatments and Mutations (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Luigi Salvagno collaborates with scholars based in Italy, Ukraine and United Kingdom. Luigi Salvagno's co-authors include Mario V. Fiorentino, Vanna Chiarion‐Sileni, Adriano Paccagnella, Vinicio Fosser, S. Monfardini, Mariella Sorarů, Savina Aversa, A. Contu, A. Fornasiero and Gino Crivellari and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Luigi Salvagno

44 papers receiving 588 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luigi Salvagno Italy 15 270 254 121 119 115 46 618
C. von Schilling Germany 11 178 0.7× 185 0.7× 65 0.5× 90 0.8× 98 0.9× 22 498
Carbone Pp United States 12 270 1.0× 137 0.5× 53 0.4× 170 1.4× 123 1.1× 28 548
Filiz Şen United States 16 213 0.8× 278 1.1× 117 1.0× 55 0.5× 112 1.0× 42 623
Sheng Yang China 16 406 1.5× 289 1.1× 63 0.5× 196 1.6× 149 1.3× 105 781
Miles Prince Australia 15 265 1.0× 199 0.8× 268 2.2× 59 0.5× 295 2.6× 49 666
Jonathan C. Yau United States 17 454 1.7× 91 0.4× 190 1.6× 197 1.7× 128 1.1× 33 768
J Chauvergne France 16 353 1.3× 228 0.9× 40 0.3× 208 1.7× 121 1.1× 107 833
Metter Ge United States 9 261 1.0× 127 0.5× 189 1.6× 53 0.4× 93 0.8× 13 538
M. Varini Switzerland 11 319 1.2× 240 0.9× 62 0.5× 184 1.5× 108 0.9× 18 646
V.J. Harvey New Zealand 11 319 1.2× 55 0.2× 52 0.4× 176 1.5× 226 2.0× 24 678

Countries citing papers authored by Luigi Salvagno

Since Specialization
Citations

This map shows the geographic impact of Luigi Salvagno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luigi Salvagno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luigi Salvagno more than expected).

Fields of papers citing papers by Luigi Salvagno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luigi Salvagno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luigi Salvagno. The network helps show where Luigi Salvagno may publish in the future.

Co-authorship network of co-authors of Luigi Salvagno

This figure shows the co-authorship network connecting the top 25 collaborators of Luigi Salvagno. A scholar is included among the top collaborators of Luigi Salvagno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luigi Salvagno. Luigi Salvagno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bernardi, Daniela, D. Errante, Enzo Galligioni, et al.. (2008). Treatment of breast cancer in older women. Acta Oncologica. 47(2). 187–198. 29 indexed citations
2.
Monfardini, S., Savina Aversa, Valerio Zoli, et al.. (2005). Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Annals of Oncology. 16(8). 1352–1358. 29 indexed citations
3.
Cattelan, Anna Maria, Luigi Salvagno, Gino Crivellari, et al.. (2005). Treatments of AIDS-related Kaposi's sarcoma. Critical Reviews in Oncology/Hematology. 53(3). 253–265. 47 indexed citations
4.
Nicoletto, Maria Ornella, Grazia Artioli, Martin Donach, et al.. (2001). Elderly Ovarian Cancer: Treatment with Mitoxantrone–Carboplatin. Gynecologic Oncology. 80(2). 221–226. 7 indexed citations
5.
6.
Agresta, Ferdinando, et al.. (2000). Gastric malt lymphomas: the value of an endoscopic follow-up evaluation. Surgical Endoscopy. 14(12). 1153–1155. 4 indexed citations
7.
Santini, Gino, P Coser, Luigi Salvagno, et al.. (2000). VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.. PubMed. 85(2). 160–6. 11 indexed citations
8.
Nicoletto, Maria Ornella, Salvatore Tumolo, Renato Talamini, et al.. (1997). Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study.. Journal of Clinical Oncology. 15(3). 994–999. 33 indexed citations
9.
Salvagno, Luigi, Mariella Sorarů, Guido Sotti, et al.. (1995). Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. Annals of Oncology. 6(2). 173–179. 2 indexed citations
10.
Sertoli, M.R., Gino Santini, Teodoro Chisesi, et al.. (1994). MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.. Journal of Clinical Oncology. 12(7). 1366–1374. 31 indexed citations
11.
Salvagno, Luigi, et al.. (1994). Prolonged Survival (17 Years) in a Patient with Chronic Myelogenous Leukemia after Therapy for Hodgkin's Disease. Leukemia & lymphoma. 16(1-2). 177–181. 7 indexed citations
12.
Salvagno, Luigi, et al.. (1993). Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy. Annals of Oncology. 4(8). 657–662. 11 indexed citations
13.
Salvagno, Luigi, A. Contu, N. Olmeo, et al.. (1992). A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Annals of Oncology. 3(10). 833–837. 34 indexed citations
14.
Fornasiero, A., et al.. (1986). Peptichemio in advanced breast cancer: a clinical evaluation in 32 patients.. PubMed. 70(5). 647–9. 3 indexed citations
15.
Paccagnella, Adriano, Luigi Salvagno, Vanna Chiarion‐Sileni, et al.. (1986). Peptichemio in pretreated patients with plasmacell neoplasms. European Journal of Cancer and Clinical Oncology. 22(9). 1053–1058. 10 indexed citations
16.
Paccagnella, Adriano, Luigi Salvagno, Alba A. Brandes, et al.. (1985). Peptichemio in pretreated patients with ovarian cancer.. PubMed. 69(1). 17–20. 11 indexed citations
17.
Salvagno, Luigi, et al.. (1985). Lipid bound sialic acid in cancer patients.. PubMed. 71(2). 127–33. 2 indexed citations
18.
Besi, Pietro De, Luigi Salvagno, Vanna Chiarion‐Sileni, et al.. (1984). Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer. European Journal of Cancer and Clinical Oncology. 20(6). 743–747. 17 indexed citations
19.
Paccagnella, Adriano, et al.. (1984). Urinary Hydroxyproline in Multiple Myeloma: Correlation with Clinical Stages and Bone Disease. Tumori Journal. 70(3). 249–253. 2 indexed citations
20.
Paccagnella, Adriano, et al.. (1983). Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. European Journal of Cancer and Clinical Oncology. 19(10). 1345–1351. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. von Schilling Breakdown of academic impact, for papers by Carbone Pp Breakdown of academic impact, for papers by Filiz Şen Breakdown of academic impact, for papers by Sheng Yang Breakdown of academic impact, for papers by Miles Prince Breakdown of academic impact, for papers by Jonathan C. Yau Breakdown of academic impact, for papers by J Chauvergne Breakdown of academic impact, for papers by Metter Ge Breakdown of academic impact, for papers by M. Varini Breakdown of academic impact, for papers by V.J. Harvey
Rankless by CCL
2026